Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Swain

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Pageof 14